LYEL
Lyell Immunopharma, Inc. Common Stock
stockNASDAQ
we are entering a new era of medicine, where cancer is treated with cellular therapies: living, smart, targeted drugs. while enormous strides have been made, especially in hematologic cancers, the full promise of these therapies still lies ahead. cell-based immunotherapies have yet to show substantial benefit in solid tumors, which represent the vast majority of cancers. our goal is nothing less than to develop curative cell-based immunotherapies for any cancer, with a focus on car-ts and solid tumors.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 9.74 | 2026-09-28 | -5.03% | -2.310 |
| 1M | 14.37 | 2026-09-04 | -35.63% | 1.515 |
| 3M | 14.04 | 2026-07-06 | -34.12% | 0.723 |
| 6M | 21.69 | 2026-04-06 | -57.35% | 1.631 |
| 1Y | 17.75 | 2025-10-03 | -47.89% | 1.665 |
| 2Y | 24.40 | 2024-10-04 | -62.09% | — |
| 5Y | 262.20 | 2021-10-04 | -96.47% | 1.601 |
Lyell Immunopharma, Inc. Common Stock (NASDAQ:LYEL) stock price today is $9.25, and today's volume is 111,391. LYEL is down 1.700% today. The 30 day average volume is 123,998. LYEL market cap is $226.67M with 24.51M shares outstanding.